Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia

Código QR

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia

Ibrahim Turkoz, Cynthia A Bossie, Bryan Dirks, Carla M CanusoOrtho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USAAbstract: Direct and indirect effects of the new psychotropic paliperidone extended-release (paliperidone ER) tablets on negative symptom improvement in schizophrenia were in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ibrahim Turkoz, Cynthia A Bossie, Bryan Dirks, Carla M Canuso
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/a85737ed2de249969bd1778a236c12c1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Role of paliperidone extended-release in treatment of schizoaffective disorder
por: Carla M Canuso, et al.
Publicado: (2010)

Paliperidone extended-release tablets in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials
por: Cai SL, et al.
Publicado: (2015)

Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
por: Yang FD, et al.
Publicado: (2017)

Effects of paliperidone extended release on hostility among Thai patients with schizophrenia
por: Jariyavilas A, et al.
Publicado: (2017)

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
por: Sliwa JK, et al.
Publicado: (2012)

The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia
por: Nakagawa R, et al.
Publicado: (2015)

The role of paliperidone extended release for the treatment of bipolar disorder
por: Marino J, et al.
Publicado: (2012)

An open-label, prospective study to evaluate social function and overall improvement of extended-release paliperidone treatment in Thai schizophrenia patients
por: Charnsil C, et al.
Publicado: (2013)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
por: Nash AI, et al.
Publicado: (2019)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs L, et al.
Publicado: (2013)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
por: Takada R, et al.
Publicado: (2018)

Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US
por: Jara M, et al.
Publicado: (2013)

Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study
por: Shi C, et al.
Publicado: (2016)

An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis
por: Si TM, et al.
Publicado: (2015)

Once-monthly paliperidone injection for the treatment of schizophrenia
por: Delia Bishara
Publicado: (2010)

The management of schizophrenia: focus on extended-release quetiapine fumarate
por: Peuskens J
Publicado: (2011)

Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan
por: Chen CY, et al.
Publicado: (2018)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
por: Li HF, et al.
Publicado: (2015)

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
por: Zhang H, et al.
Publicado: (2016)

Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
por: O'Donnell A, et al.
Publicado: (2021)

Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders
por: El-Khalili N
Publicado: (2012)

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
por: Gopal S, et al.
Publicado: (2020)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
por: Zhang F, et al.
Publicado: (2015)

Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development
por: Gregory P. Strauss, et al.
Publicado: (2021)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
por: Mathews M, et al.
Publicado: (2019)

Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia
por: Sicras-Mainar A, et al.
Publicado: (2014)

Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment
por: Aleksandr M. Reznik, et al.
Publicado: (2020)

Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study
por: Li H, et al.
Publicado: (2018)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
por: Brasso C, et al.
Publicado: (2017)

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
por: Mathews M, et al.
Publicado: (2018)

Pain perception in schizophrenia: influence of neuropeptides, cognitive disorders, and negative symptoms
por: Urban-Kowalczyk M, et al.
Publicado: (2015)

Interaction between paliperidone extended release and TS-1&reg;, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient
por: Yasui-Furukori N, et al.
Publicado: (2013)

Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm
por: Cerveri G, et al.
Publicado: (2019)

Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review
por: Zhang LL, et al.
Publicado: (2016)

Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics
por: Li N, et al.
Publicado: (2018)

Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
por: Lopez A, et al.
Publicado: (2019)

Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment
por: Correll CU, et al.
Publicado: (2020)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
por: Emsley R, et al.
Publicado: (2018)

Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability
por: Gattaz WF, et al.
Publicado: (2020)

Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study
por: Liang Y, et al.
Publicado: (2017)